XeNA: Capecitabine Plus Docetaxel, With or Without Trastuzumab, as Preoperative Therapy for Early Breast Cancer

News  |  www.medsci.org | Jan 1, 1970

Combinations of capecitabine and a taxane are highly active in metastatic breast cancer, and synergy between capecitabine and docetaxel has also been demonstrated. Such combinations potentially would provide a promising nonanthracycline-based alternative for patients with early breast

http://www.medsci.org/v05p0341.htm

Agennix - Protein Therapeutics for Cancer and Diabetes

Agennix is a private biotechnology company developing a first-in-class molecule with activity in several types of cancer and in other indications with unmet medical needs. Talactoferrin is a targeted dendritic cell recruiter and activator (DCRA) with a novel mechanism of action.

http://www.agennix.com/

Troponins for predicting cardiotoxicity from cancer therapy : The Lancet

News  |  www.thelancet.com

Troponins for predicting cardiotoxicity from cancer therapy. By - Joseph A Sparano, Antonio C Wolff, David Brown

http://www.thelancet.com/journals/lancet/article/PIIS0140-6736(00)03304-3

Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018

Press Release  |  www.prnewswire.com | Nov 9, 2009

Sales of HER2-Targeting Agents for Breast Cancer, Including Herceptin and Tykerb/Tyverb, Will Grow by 3.3 Percent Annually from 2008 to 2018. Incidence of Breast Cancer Will Increase by 1.2 Percent Annually Through 2018 in the World's Major Markets, According to a New Report from Decision Resources.

http://www.prnewswire.com/news-releases/sales-of-her2-targeting-agents-for-breast-cancer-including-herceptin-and-tykerbtyverb-will-grow-by-33-percent-annually-from-2008-to-2018-69553687.html

Targeted Therapies for Cancer: ImmunoGen, Inc.

ImmunoGen, Inc. develops targeted anticancer therapeutics. Our proprietary Tumor-Activated Prodrug (TAP) technology and strong antibody expertise form the basis for our development of our own products as well as of our partnerships with other companies.

http://www.immunogen.com/

ROCHE-layoutV2.indd

Web  |  medischcontact.artsennet.nl

Karolinska Institutet in collaboration with Stockholm School of Economics Stockholm, Sweden Foreword One of the great triumphs of scientific research has been to advance our knowledge of the causes and pathophysiology of malignancy.

http://medischcontact.artsennet.nl/web/file?uuid=d87b8d48-a0ca-4404-9e88-797ed822fbf4&owner=bf105ffe-1e09-4d4c-9468-e865b9063f7a

Gen-Probe Broadens Intellectual Property Portfolio For Automated Nucleic Acid Testing

News  |  www.pharmaceutical-business-review.com

Patents relate to automated sample preparation and target nucleic acid amplification

http://www.pharmaceutical-business-review.com/news/genprobe_broadens_intellectual_property_portfolio_for_automated_nucleic_acid_testing_090804

Apria - resources - News

Genentech Inc notified doctors of 36 cases of eye inflammation among patients who received injections with the company's Avastin colon cancer drug for unapproved eye conditions.

http://www.apria.com/resources/1,2725,494-863198,00.html

ScienceDirect - Seminars in Arthritis and Rheumatism, Articles in Press

Web  |  www.sciencedirect.com

ScienceDirect - the world's leading platform offers over 2,000 high quality peer-reviewed full-text journals and books on science, technology and medicine.

http://www.sciencedirect.com/science?_ob=PublicationURL&_tockey=%23TOC%237142%239999%23999999999%2399999%23FLA%23&_cdi=7142&_pubType=J&view=c&_auth=y&_version=1&_urlVersion=0&_userid=10&md5=e6b05b057a2af9e893b40ed02fd9c9f3

Researchers study Rituximab's action on cancer stem cells

News  |  www.news-medical.net | Apr 14, 2008

Preliminary data from one of the first clinical trials to test a stem cell-targeting drug in cancer patients shows that while the drug did not prolong survival, its suppressing effect on patients' stem cells was impressive enough to send investigators looking for a better drug to try. Preliminary

http://www.news-medical.net/?id=37329